Kazia Therapeutics Limited (KZIA) News
Filter KZIA News Items
KZIA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KZIA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest KZIA News From Around the Web
Below are the latest news stories about KAZIA THERAPEUTICS LTD that investors may wish to consider to help them evaluate KZIA as an investment opportunity.
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offeringKazia Therapeutics (KZIA) announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the company’s American Depositary Shares, each ADS representing 100 ordinary shares of the company, at a purchase price of $1.50 per ADS, in a registered direct offering. The company has also agreed to issue, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 1,333,333 ADSs. The warrants will have an exercise p |
Kazia Therapeutics Announces $2.0 Million Registered Direct OfferingKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing 100 ordinary shares of the Company, at a purchase price of $1.50 per ADS (or ADS equivalent in lieu thereof), in a registered direct offering. The |
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with the FDA. In July 2024, the company reported topline results from the GBM-AGILE study in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed a clinically meaningful improvement in a prespecified secondary analysis for overall survival (OS) compared to standard |
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDAKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA). |
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer SymposiumKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium highlighting the activity the Company's lead product candidate, paxalisib, for the potential treatment of immunotherapy-resistant triple negative breast cancer (TNBC) and HER2 positive metastatic breast cancer with active brain metastases. |
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma MultiformeKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia's blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM. |
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq ListingKazia Therapeutics (KZIA) has released an update. Kazia Therapeutics plans to modify the ratio of its American Depositary Shares (ADS) to improve its trading price on Nasdaq, with the new ratio set to take effect on October 28, 2024. This change aims to help the company meet Nasdaq’s minimum bid price requirement, but there is no guarantee it will succeed. The adjustment will not affect the number of underlying Ordinary Shares, and the company’s stock will continue to trade under the ticker symb |
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual MeetingKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting (ASTRO 2024), which is taking place from September 29 - October 2, 2024, in Washi |
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington. |
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination). |